Compare GLNG & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLNG | VTAK |
|---|---|---|
| Founded | 1946 | 2002 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 3.0M |
| IPO Year | 2002 | 2018 |
| Metric | GLNG | VTAK |
|---|---|---|
| Price | $49.68 | $1.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $50.63 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 3.3M |
| Earning Date | 11-21-2023 | 08-11-2026 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ 89.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $442,000.00 |
| Revenue This Year | $3.14 | $1,170.33 |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | $80.48 | ★ N/A |
| Revenue Growth | N/A | ★ 3057.14 |
| 52 Week Low | $35.02 | $0.15 |
| 52 Week High | $57.79 | $4.31 |
| Indicator | GLNG | VTAK |
|---|---|---|
| Relative Strength Index (RSI) | 40.39 | 61.63 |
| Support Level | $48.48 | $1.14 |
| Resistance Level | $52.41 | $1.22 |
| Average True Range (ATR) | 1.24 | 0.18 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 35.61 | 35.68 |
Golar LNG Ltd designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas and provides floating liquefied natural gas (FLNG) services. It offers solutions for gas resource holders to develop and utilize gas reserves, including stranded, associated, flared, or underutilized resources. The company's reportable segments are: i) FLNG: includes the operations of FLNG vessels and projects, and ii) Corporate and other: includes legacy shipping segment activities, vessel management, floating storage and regasification unit services for third parties. The majority of the company's revenue is derived from the FLNG segment. Geographically, it generates the maximum revenue from Cameroon.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.